FDA seeking more info on Avedro's corneal cross-linking NDA ModernMedicine "Patients with these sight-threatening conditions may require corneal transplant surgery. If approved, the riboflavin ophthalmic solution/KXL System would be the first FDA-approved therapeutic treatment for these orphan indications," the company said. |
